Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection
Gespeichert in:
| Titel: | Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection |
|---|---|
| Autoren: | Beom Kyung Kim, Kwang Hyub Han, Sang Hoon Ahn |
| Weitere Verfasser: | Kim B.K., Han K.-H., Ahn S.H., Kim, Beom Kyung, Ahn, Sang Hoon, Han, Kwang Hyup |
| Quelle: | Oncology. 81:41-49 |
| Verlagsinformationen: | S. Karger AG, 2011. |
| Publikationsjahr: | 2011 |
| Schlagwörter: | 0301 basic medicine, Hepatitis B virus, Carcinoma, Hepatocellular, Hepatocellular carcinoma, Hepatocellular/prevention & control, Antiviral therapy, Hepatocellular/therapy, Chronic/complications, Chronic/drug therapy, Chronic hepatitis B, Antiviral Agents, 03 medical and health sciences, Hepatitis B, Chronic, Hepatitis B Vaccines/administration & dosage, Hepatitis B virus/physiology, Chronic/prevention & control, Secondary Prevention, Tertiary Prevention, Humans, Hepatitis B Vaccines, Early Detection of Cancer, Antiviral Agents/therapeutic use, Liver Neoplasms/epidemiology, 0303 health sciences, Interferons/therapeutic use, Hepatocellular/virology, Liver Neoplasms/prevention & control, Prevention, Carcinoma, Liver Neoplasms, Liver Neoplasms/therapy, HBV vaccine, Hepatitis B, 3. Good health, Primary Prevention, Chronic/virology, Disease Progression, Interferons, Hepatocellular/epidemiology |
| Beschreibung: | Chronic hepatitis B (CHB) accounts for approximately 50% of the underlying etiologies for the development of hepatocellular carcinoma (HCC) worldwide. We reviewed the primary, secondary, and tertiary measures for the prevention of HCC in CHB patients. First, the most effective method is preventing the acquisition of CHB through global vaccination of infants. However, in patients already chronically infected, antiviral treatment using interferon or nucleoside analogs can prevent disease progression to cirrhosis or HCC. Studies have found viral replications indicated by a HBV DNA level to be a strong predictor for cirrhosis and HCC, irrespective of other viral and biochemical factors. Additionally, periodic surveillance using ultrasonography and serum α-fetoprotein every 3–6 months for earlier detection of HCC is also important so that curative treatments can be used. Once HCC occurs, hepatic resection is the mainstay of curative treatments. To prevent tumor recurrence after resection, adjuvant interferon treatments have been tried with promising results based on the assumption that they not only suppress viral activity but also have tumoricidal, antiangiogenetic, and antiproliferative effects. Using nucleoside analogs also has its rationale for preventing de novo tumor development in remnant liver, considering that viral replications are a strong risk factor for HCC. Optimal preventive plans should be further investigated in future studies. |
| Publikationsart: | Article |
| Dateibeschreibung: | 41~49 |
| Sprache: | English |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000333258 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/22212935 https://www.ncbi.nlm.nih.gov/pubmed/22212935 https://pubmed.ncbi.nlm.nih.gov/22212935/ https://ir.ymlib.yonsei.ac.kr/handle/22282913/94927 https://www.karger.com/Article/FullText/333258 https://yonsei.pure.elsevier.com/en/publications/prevention-of-hepatocellular-carcinoma-in-patients-with-chronic-h https://mdanderson.elsevierpure.com/en/publications/prevention-of-hepatocellular-carcinoma-in-patients-with-chronic-h |
| Rights: | CC BY NC ND URL: https://www.karger.com/Services/SiteLicenses |
| Dokumentencode: | edsair.doi.dedup.....fde698ad2801103da76268638d7ec9bb |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Chronic hepatitis B (CHB) accounts for approximately 50% of the underlying etiologies for the development of hepatocellular carcinoma (HCC) worldwide. We reviewed the primary, secondary, and tertiary measures for the prevention of HCC in CHB patients. First, the most effective method is preventing the acquisition of CHB through global vaccination of infants. However, in patients already chronically infected, antiviral treatment using interferon or nucleoside analogs can prevent disease progression to cirrhosis or HCC. Studies have found viral replications indicated by a HBV DNA level to be a strong predictor for cirrhosis and HCC, irrespective of other viral and biochemical factors. Additionally, periodic surveillance using ultrasonography and serum α-fetoprotein every 3–6 months for earlier detection of HCC is also important so that curative treatments can be used. Once HCC occurs, hepatic resection is the mainstay of curative treatments. To prevent tumor recurrence after resection, adjuvant interferon treatments have been tried with promising results based on the assumption that they not only suppress viral activity but also have tumoricidal, antiangiogenetic, and antiproliferative effects. Using nucleoside analogs also has its rationale for preventing de novo tumor development in remnant liver, considering that viral replications are a strong risk factor for HCC. Optimal preventive plans should be further investigated in future studies. |
|---|---|
| ISSN: | 14230232 00302414 |
| DOI: | 10.1159/000333258 |